首页> 外文期刊>Nuclear Medicine and Biology >Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with (177)Lu: in vitro comparison of acyclic and macrocyclic ligands.
【24h】

Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with (177)Lu: in vitro comparison of acyclic and macrocyclic ligands.

机译:用(177)Lu标记内在化的抗表皮生长因子受体变体III单克隆抗体:无环和大环配体的体外比较。

获取原文
获取原文并翻译 | 示例
           

摘要

INTRODUCTION: The monoclonal antibody (mAb) L8A4, reactive with the epidermal growth factor receptor variant III (EGFRvIII), internalizes rapidly in glioma cells after receptor binding. Combining this tumor-specific mAb with the low-energy beta-emitter (177)Lu would be an attractive approach for brain tumor radioimmunotherapy, provided that trapping of the radionuclide in tumor cells after mAb intracellular processing could be maximized. MATERIALS AND METHODS: L8A4 mAb was labeled with (177)Lu using the acyclic ligands [(R)-2-amino-3-(4-isothiocyanatophenyl)propyl]-trans-(S,S)-cyclohexane-1,2-diamin e-pentaacetic acid (CHX-A''-DTPA), 2-(4-isothiocyanatobenzyl)-diethylenetriaminepenta-acetic acid (pSCN-Bz-DTPA) and 2-(4-isothiocyanatobenzyl)-6-methyldiethylenetriaminepentaacetic acid (1B4M-DTPA), and the macrocyclic ligands S-2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-tetraacetic acid (C-DOTA) and alpha-(5-isothiocyanato-2-methoxyphenyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10- tetraacetic acid (MeO-DOTA). Paired-label internalization and cellular processing assays were performed on EGFRvIII-expressing U87.DeltaEGFR glioma cells over 24 h to directly compare (177)Lu-labeled L8A4 to L8A4 labeled with (125)I using either iodogen or N-succinimidyl 4-guanidinomethyl-3-[(125)I]iodobenzoate ([(125)I]SGMIB). In order to facilitate comparison of labeling methods, the primary parameter evaluated was the ratio of (177)Lu to (125)I activity retained in U87.DeltaEGFR cells. RESULTS: All chelates demonstrated higher retention of internalized activity compared with mAb labeled using iodogen, with (177)Lu/(125)I ratios of >20 observed for the three DTPA chelates at 24 h. When compared to L8A4 labeled using SGMIB, except for MeO-DOTA, internalized activity for (125)I was higher than (177)Lu from 1-8 h with the opposite behavior observed thereafter. At 24 h, (177)Lu/(125)I ratios were between 1.5 and 3, with higher values observed for the three DTPA chelates. CONCLUSIONS: The nature of the chelate used to label this internalizing mAb with (177)Lu influenced intracellular retention in vitro, although at early time points, only MeO-DOTA provided more favorable results than radioiodination of the mAb via SGMIB.
机译:简介:与表皮生长因子受体变体III(EGFRvIII)反应的单克隆抗体(mAb)L8A4在受体结合后迅速在神经胶质瘤细胞中内化。将这种肿瘤特异性mAb与低能β-发射体(177)Lu结合起来,将是脑肿瘤放射免疫疗法的一种有吸引力的方法,前提是可以最大程度地利用mAb细胞内加工后将放射性核素截留在肿瘤细胞中。材料与方法:使用无环配体[(R)-2-氨基-3-(4-异硫氰酸根合苯基)丙基]-反-(S,S)-环己烷-1,2-(L)将L8A4 mAb标记为(177)Lu。氨基戊五乙酸(CHX-A''-DTPA),2-(4-异硫氰酸根合苄基)-二亚乙基三胺五乙酸-(pSCN-Bz-DTPA)和2-(4-异硫氰酸根合苄基)-6-甲基二亚乙基三胺五乙酸(1B4M- DTPA)和大环配体S-2-(4-异硫氰酸根合苄基)-1,4,7,10-四氮杂环十二烷-四乙酸(C-DOTA)和α-(5-异硫氰酸根合-2-甲氧基苯基)-1,4 1,7,10-四氮杂环十二烷-1,4,7,10-四乙酸(MeO-DOTA)。在表达EGFRvIII的U87.DeltaEGFR神经胶质瘤细胞上进行配对标记内化和细胞处理实验,时间为24小时,以使用碘或N-琥珀酰亚胺基4-胍基甲基直接比较(177)Lu标记的L8A4与标有(125)I的L8A4 -3-[(125)I]碘苯甲酸酯([(125)I] SGMIB)。为了便于比较标记方法,评估的主要参数是保留在U87.DeltaEGFR细胞中的(177)Lu与(125)I活性之比。结果:与使用碘标记的mAb相比,所有螯合物均表现出更高的内在活性保留,在24 h时观察到三种DTPA螯合物的(177)Lu /(125)I比> 20。当与使用SGMIB标记的L8A4进行比较时,除了MeO-DOTA以外,(125)I的内在活性在1-8小时内高于(177)Lu,此后观察到相反的行为。在24小时时,(177)Lu /(125)I之比在1.5和3之间,对于三种DTPA螯合物观察到更高的值。结论:用(177)Lu标记此内在化mAb的螯合物的性质影响了体外细胞内保留,尽管在较早的时间点,仅MeO-DOTA比通过SGMIB进行碘化放射性碘化效果更好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号